» Articles » PMID: 8992967

Costimulation of CD28- T Lymphocytes by 4-1BB Ligand

Overview
Journal J Immunol
Date 1997 Jan 15
PMID 8992967
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction of the T cell surface protein CD28 with its ligand, B7-1 or B7-2, provides a critical costimulatory signal for T cell activation. T cells from CD28- mice are deficient in a variety of responses, including those to lectins and allogeneic spleen cells. However, some immune responses do occur in CD28- mice, suggesting the existence of alternate costimulatory pathways. In this work, we show that T cells purified from CD28- mice respond to B lymphomas expressing 4-1BB ligand (4-1BBL), a member of the TNF gene family. This response is inhibited by a soluble form of 4-1BB, the T cell surface receptor for 4-1BBL. Thus, 4-1BBL/4-1BB interaction provides costimulatory signals to T cells independent of signaling through the CD28 receptor. We find that 4-1BBL is inducible on splenic B cells by CD40 ligand/CD40 interaction or by culturing of splenic dendritic cells, treatments that also induce B7 family molecules. CD28- T cells fail to respond in an MLR to resting allogeneic spleen cells. However, treatment of spleen cells with CD40 ligand renders them competent in activation of CD28- T cells. In contrast to results using B lymphomas as APC, soluble 4-1BB fails to inhibit the T cell response to activated spleen cells. This failure of soluble 4-1BB to block an MLR between CD28+ or CD28- T cells and allogeneic spleen cells is in contrast to a previous report with CD28+ cells.

Citing Articles

Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.

Du G, Dou C, Sun P, Wang S, Liu J, Ma L Front Immunol. 2024; 15:1431211.

PMID: 39136031 PMC: 11317284. DOI: 10.3389/fimmu.2024.1431211.


Interactions Between HDL and CD4+ T Cells: A Novel Understanding of HDL Anti-Inflammatory Properties.

Atehortua L, Davidson W, Chougnet C Arterioscler Thromb Vasc Biol. 2024; 44(6):1191-1201.

PMID: 38660807 PMC: 11111342. DOI: 10.1161/ATVBAHA.124.320851.


Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.

Khushalani N, Ott P, Ferris R, Cascone T, Schadendorf D, Le D J Immunother Cancer. 2024; 12(3).

PMID: 38458639 PMC: 10921538. DOI: 10.1136/jitc-2023-007364.


4-1BB: A promising target for cancer immunotherapy.

Kim A, Nemeth M, Lim S Front Oncol. 2022; 12:968360.

PMID: 36185242 PMC: 9515902. DOI: 10.3389/fonc.2022.968360.


The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes.

Rojas M, Heuer L, Zhang W, Chen Y, Ridgway W Front Immunol. 2022; 13:918837.

PMID: 35935980 PMC: 9353112. DOI: 10.3389/fimmu.2022.918837.